Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425210 | 0.82 | GAA (0.37) | CA1CA2CA9CHEK1WEE1 | |
| SCHEMBL26616696 | 0.72 | PIM1 (0.38) | CA1CA2CA9 | |
| SCHEMBL3046283 | 0.70 | MAPT (0.40) | CHEK1WEE1GSK3B | |
| SCHEMBL29441220 | 0.67 | PARP1 (0.43) | CA1CA2CA9CHEK1WEE1 | |
| SCHEMBL11518277 | 0.67 | PARP1 (0.43) | CA1CA2CA9CHEK1WEE1 | |
| SCHEMBL3037404 | 0.66 | TDP2 (0.37) | — | |
| SCHEMBL3048579 | 0.66 | CHEK1 (0.43) | CA1CA2CA9CHEK1WEE1 | |
| SCHEMBL3039233 | 0.65 | MEN1 (0.50) | CA1CA2CA9CHEK1WEE1 | |
| SCHEMBL31717008 | 0.65 | MEN1 (0.50) | CA1CA2CA9CHEK1WEE1 | |
| SCHEMBL10796712 | 0.64 | CA1 (0.50) | CA1CA2CA9CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7645557-B2 | Positive resist composition for immersion exposure and pattern forming method using the same | FUJIFILM CORPORATION (JP) | 2010-01-12 | — | — | US | disclosed |
| EP-2108642-A1 | JAK INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-10-14 | — | — | EP | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
| EP-1767992-A1 | Positive resist composition for immersion exposure and pattern forming method using the same | FUJIFILM Corporation (JP) | 2007-03-28 | — | — | EP | disclosed |
| US-20070065753-A1 | Positive resist composition for immersion exposure and pattern forming method using the same | FUJI PHOTO FILM CO., LTD. | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | CA1 1603/4885CA2 1798/4885CA9 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.